Company news
Kane Biotech Inc. (TSXV:KNE) news
Every Kane Biotech Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Kane Biotech’s revyve® Research Presented at Military Health System Research Symposium
August 25, 2026
Kane Biotech Announces Engagement of DNA Advisors
August 5, 2026
Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
July 2, 2026
Kane Biotech Announces Grant of Stock Options
May 29, 2026
Kane Biotech Announces First Quarter 2026 Financial Results
May 28, 2026
Kane Biotech Announces the Oversubscription and Closing of Private Placement Offering
May 26, 2026
Kane Biotech Presents Data To Global Wound Care Community at WCET®-NSWOCC® 2026 Joint Congress
May 13, 2026
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
April 23, 2026
Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference
April 16, 2026
Kane Biotech Presents revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference
April 16, 2026
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
March 17, 2026
Kane Biotech Expands U.S. Commercial Footprint with Strategic Distribution Partnership
March 10, 2026
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
February 20, 2026
Kane Biotech Announces Publication of revyve® Wound Gel Article in the International Wound Journal
February 20, 2026
Kane Biotech Expands Commercial Activities in the United States
February 19, 2026
Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
February 17, 2026
Kane Biotech Announces FDA 510(k) Clearance for revyve® Antimicrobial Skin and Wound Cleanser
February 17, 2026
Kane Biotech Restarts Commercial Activities and Strengthens North American Management
February 12, 2026
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
December 18, 2025
Kane Biotech Presents New Data at Innovations in Wound Healing Annual Meeting
December 17, 2025
Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
December 10, 2025
Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray
December 10, 2025
Kane Biotech Announces Third Quarter 2025 Financial Results
November 28, 2025
Kane Biotech Announces New Private Placement Offering
November 27, 2025
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
November 4, 2025
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
November 4, 2025
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
September 16, 2025
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
September 16, 2025
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
September 10, 2025
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
September 10, 2025
Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference
September 4, 2025
Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference
September 4, 2025
Kane Biotech Announces Second Quarter 2025 Financial Results
August 28, 2025
Kane Biotech Showcases revyve™ Preclinical and Clinical Case Study Findings at North American Wound Care Conferences
July 30, 2025
Kane Biotech Showcases revyve(TM) Preclinical and Clinical Case Study Findings at North American Wound Care Conferences
July 30, 2025
Kane Biotech to Present at Advanced Wound Care Summit USA
July 14, 2025
Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting R...
June 26, 2025
Kane Biotech Provides Further Corporate Update
June 18, 2025
Kane Biotech Announces First Quarter 2025 Financial Results
May 29, 2025
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
May 5, 2025
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
April 28, 2025
Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
April 11, 2025
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
March 13, 2025
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
March 13, 2025
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
March 11, 2025
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve(TM) Antimicrobial Wound Gel
March 11, 2025
Kane Biotech Announces Second and Final Closing of Private Placement Offering
February 19, 2025
Canadian Investment Regulatory Organization Trade Resumption - KNE
November 12, 2024
Canadian Investment Regulatory Organization Trading Halt - KNE
November 12, 2024
IIROC Trading Resumption - KNE
May 25, 2023